Translated Summaries

In The Journal of Regulation the summaries’ translation are done by the Editors and not by the authors

ENGLISH

On December 5, 2011, the United States Postal Service, an agency of the federal government, announced that it would close 252 of its mail processing centers by March 2012, thereby ending the expectation for next-day delivery of intra-zone first-class mail and increasing all delivery times by one day, as well as seek legislative approval for a plethora of other service cuts.

FRENCH

Le 5 décembre 2011, La Poste américaine, une agence fédérale, a annoncé qu’elle fermerait 252 de ses centres de courrier d’ici mars 2012 ainsi mettant fin à la livraison J+1 pour le courrier prioritaire intra-zone et rajoutant un jour à la livraison de tout autre pli, et qu’elle demanderait au Congrès l’autorisation d’effectuer des coupures de service plus significatives encore.

ITALIAN

Il 5 dicembre 2011 il servizio postale degli Stati Uniti, agenzia del governo federale, ha annunciato che chiuderà 252 centri di smistamento per la fine del mese di marzo 2012, mettendo fine alla consegna in 24 ore di posta di prima classe aumentando i tempi di consegna di un giorno. L’agenzia ha inoltre richiesto l’autorizzazione del legislatore per altri tagli di servizio.

 

....................

Other translations forthcoming.

 

In response to the scandal of the drug called the" Médiator", politics, believing that the regulatory authority of medicinal product had not correctly done his job, responded by an act on December, 29 2011 providing the replacement of Agence française de sécurité sanitaire des produits de santé (Afssaps-) (French Agency for the Safety of Health Product) by The Agence Nationale de Sécurité du Médicament (ANSM) (National Agency for safety of medicinal product). The implementing decree organising the regulatory authority was released on April 29, 2012, that allowing the effective implementation of the new authority on the scheduled date: 1 may 2012. There is continuity between the two authorities: it is the same Professor of medicine who is the executive chairman, who was appointed at the head of the Agence française de sécurité sanitaire des produits de santé (Afssaps-) (French Agency for the Safety of Health Product) following the case of the" Médiator", and became the executive chairman of the (National Agency for safety of medicinal product). But the new authority must strengthen its own expertise; this allows therefore an increased autonomy to avoid capture by asymmetry of information for the benefit of pharmaceutical laboratories. The new Act also wants to avoid the links of interests, which lead to the same result of ineffectiveness of the control, and with a focus on transparency as an operating principle.